| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2caa65b95c54b77adfc4d77fcadd8514
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b04d1dfd8f669ba06bbeeebdb8d06995
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d1f04761266f2eb331645358213b70d3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-08 |
| filingDate |
1995-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47d9283d182ea0ab77a6f2645d8c3879
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7349b2f9daedc71ed14882bfdc48cd56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24e9ced935eda77dc6a7a7f94757369b |
| publicationDate |
1996-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9609821-A1 |
| titleOfInvention |
Inhibitors of farnesyl-protein transferase |
| abstract |
The present invention comprises analogs of the CA1A2X motif of the protein Ras that is modified by farnesylation in vivo. These CA1A2X analogs inhibit the farnesylation of Ras. Furthermore, these CA1A2X analogs differ from those previously described as inhibitors of Ras farnesly transferase in that they have a prolyl like moiety in the A1 position. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6946468-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5734013-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7101897-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9807692-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6232338-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9706138-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6777438-B2 |
| priorityDate |
1994-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |